What factors drove the changes in uniQure's revenue and profit?

Did uniQure beat or miss consensus estimates last quarter?

What were the key takeaways from uniQure’s earnings call?

What is the market's earnings forecast for uniQure next quarter?

What guidance did uniQure's management provide for the next earnings period?

What is the revenue and EPS growth rate for uniQure year over year?

What is uniQure's gross profit margin?

What were the key takeaways from uniQure's earnings call?

- **AMT-130 Data Strength**: 75% disease progression slowing at 3 years vs. external control; 4-year follow-up planned to confirm durability.
- **FDA Regulatory Hurdle**: Agency insists on Phase III sham-controlled trial despite natural history data precedent.
- **Ex-U.S. Regulatory Path**: Pursuing MHRA/EMA engagement for expedited access via named patient programs.
- **Financial Resilience**: $622M cash runway supports multiple late-stage programs; AMT-130 commercialization expenses up 24%.

**【CEO Summary Section】**
- AMT-130 for Huntington's disease (HD) showed statistically significant 75% slowing of disease progression at 3 years vs. external control, with no safety concerns beyond procedure-related risks.
- FDA recommended a Phase III double-blind sham-controlled study, despite company's argument for leveraging extensive natural history data (e.g., Enroll HD with 30,000+ participants).
- Company plans to update Phase I/II statistical analysis plan for 4-year follow-up and pursue ex-U.S. regulatory pathways.

**【CFO Financial Commentary】**
- 2025 revenue: $16.1M (down 41% vs. 2024) due to $10.7M decline in collaboration revenue and $6.1M drop in contract manufacturing, offset by $5.8M increase in license revenue.
- R&D expenses: $140.7M (down 2% vs. 2024), driven by $26M reduction in restructuring costs, partially offset by $19.4M for AMT-130 BLA preparation.
- SG&A: $65.5M (up 24%), including $6.5M for AMT-130 commercialization.
- Cash: $622.5M as of Q4 2025, up 69% vs. 2024, supporting operations into H2 2026.

**【Q&A Key Highlights】**
- **FDA Engagement**: FDA emphasized need for Phase III sham-controlled trial despite company's argument for external control comparators. Company will request Type B meeting in Q2 to discuss Phase III design.
- **Ex-U.S. Strategy**: Exploring named patient programs and early access in Europe (MHRA, EMA) and other regions with strong natural history data.
- **AMT-130 Cost Considerations**: Feasibility of sham-controlled trial weighed against patient burden; no decision yet on partnering.
- **Pipeline Updates**: AMT-191 (Fabry) shows durable enzyme activity in all 11 patients; AMT-260 (TLE) shows seizure reduction in first 6 patients with >6 months follow-up.
- **Financial Flexibility**: Strong cash position supports multiple late-stage programs, but Phase III cost estimates pending design clarity.

uniQure N.V.(QURE)-20260302-2025 Q4 Earnings call transcript

- **AMT-130 Regulatory Hurdle**: FDA unexpectedly questions Phase I/II data sufficiency for BLA, delaying timeline.
- **Pipeline Progress**: AMT-260 epilepsy and AMT-191 Fabry disease programs advancing, with data coming in H1 2026.
- **Financial Strength**: $649M cash runway supports multi-regulatory engagement.
- **Key Risk**: Dose-limiting toxicity in AMT-162 ALS program halts enrollment.
- **Global Strategy**: EU/UK regulatory paths being explored post-US progress.

**【Management Opening Remarks】**
- Presented positive top-line data from the pivotal Phase I/II study of AMT-130 in Huntington's disease (HD), showing statistically significant slowing of disease progression.
- Highlighted unexpected FDA feedback that the Phase I/II data may not suffice for BLA submission, introducing regulatory uncertainty.
- Emphasized commitment to working with FDA and other regulators to advance AMT-130 globally.

**【CEO Summary Section 1】**
- AMT-130 demonstrated 75% slowing of disease progression vs. external control, with neurofilament biomarker support.
- FDA feedback indicated Phase I/II data alone may not meet BLA requirements, requiring additional discussions.
- Noted the company's financial strength (cash of $649M) and focus on expeditious regulatory paths.

**【CEO Summary Section 2】**
- AMT-162 ALS program paused due to dose-limiting toxicity in the second cohort.
- AMT-260 epilepsy and AMT-191 Fabry disease programs progressing, with data expected in H1 2026.
- Reiterated confidence in AMT-130's potential despite FDA uncertainty.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $3.7M (vs. $2.3M YoY), driven by license revenue growth.
- R&D expenses: $34.4M (vs. $30.6M YoY), including BLA preparation costs.
- SG&A: $19.4M (vs. $11.6M YoY), reflecting commercialization prep.
- Cash runway extended to 2029, supporting regulatory and clinical activities.

**【Q&A Highlights】**
- **Regulatory Path**: FDA feedback unpredictability; EMA/MHRA engagement planned post-FDA clarity.
- **Pipeline Risks**: Dose-dependent toxicity in AMT-162; external control methodology scrutiny.
- **Stakeholder Engagement**: Strong physician/patient demand vs. regulatory caution.
- **Financial Resilience**: $649M cash with no near-term dilution needs.

uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript

- **AMT-130 Regulatory Milestone**: FDA alignment on SAP and CMC for BLA submission in Q1 2026; 3-year cUHDRS data readout expected in September.
- **Clinical Pipeline Progress**: AMT-260 shows 92% seizure reduction in first patient; AMT-191 initial data coming in September.
- **Financial Strength**: $377 million cash balance supports operations into 2027; Q2 revenue $5.3 million with R&D expenses $35.4 million.
- **Commercial Readiness**: 50+ U.S. centers capable of administering AMT-130; hiring key launch roles and developing integrated strategy.

**【CEO Summary Section】**
- AMT-130 for Huntington's disease (HD) is on track for a BLA submission in Q1 2026, with regulatory alignment on statistical analysis plan (SAP) and manufacturing (CMC) requirements.
- Expanded clinical pipeline progress: AMT-191 (Fabry disease) initial data expected in September, AMT-260 (mesial temporal lobe epilepsy) showing 92% seizure reduction in first patient, and AMT-162 (SOD1-ALS) dosing ongoing.
- Commercial launch preparation underway, including hiring key roles and developing integrated launch strategy.

**【CMO Clinical Update】**
- AMT-130: Final SAP submitted to FDA using propensity score matched external control from ENROLL-HD. PPQ campaign initiated, with 3-year data cutoff achieved for September 2025 readout.
- AMT-260: 14 U.S. sites screening for mesial temporal lobe epilepsy trial; first patient shows 92% seizure reduction over 5 months.
- AMT-191: Initial safety and efficacy data expected at ICIEM conference in September.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $5.3 million (down 51% YoY) due to contract manufacturing divestment.
- R&D expenses: $35.4 million (up 5% YoY) driven by external program spend and contingent consideration.
- Cash position: $377 million as of June 30, 2025, supporting operations into H2 2027.

**【Q&A Highlights】**
- FDA alignment on AMT-130: No minimum clinical benefit threshold required; focus on 3-year cUHDRS data vs. ENROLL-HD control.
- Patient eligibility: Expanded cohort for lower striatal volume patients, with safety data collection underway.
- Commercial infrastructure: 50+ U.S. neurosurgical centers capable of administering AMT-130; launch expected in 2026 if BLA approved.
- Regulatory path: Accelerated approval sought; potential confirmatory trial design to be determined post-BLA submission.

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

- **Strong Cash Position**: $409M as of Q1 2025, supporting operations into H2 2027
- **AMT-130 Milestones**: Breakthrough Therapy Designation achieved; BLA submission expected later this year
- **Pipeline Expansion**: 3 new clinical trials initiated in epilepsy, Fabry disease, and ALS
- **Cost Management**: R&D expenses down 11% YoY; SG&A down 22% YoY
- **FDA Engagement**: Productive regulatory interactions; no delays anticipated from new leadership


**【CEO Summary Section】**
- Q1 2025 revenue was $1.6 million, down 81% YoY due to the divestiture of the Lexington manufacturing facility. 
- AMT-130 for Huntington's disease achieved Breakthrough Therapy Designation in April 2025 and remains on track for BLA submission later this year.
- Expanded clinical pipeline with 3 new trials initiated in refractory temporal lobe epilepsy (AMT-260), Fabry disease (AMT-150), and SOD1-ALS (AMT-162).
- Strong cash position of $409M as of March 31, 2025, supporting 2027+ operational runway.

**【CFO Financial Update】**
- Q1 2025 financial highlights:
  - Revenue: $1.6M (down from $8.5M YoY)
  - R&D expenses: $36.1M (down 11% YoY)
  - SG&A expenses: $10.9M (down 22% YoY)
  - Cash balance: $409M (up 11% QoQ)
- $80M follow-on equity offering completed in Q1.
- No near-term capital needs beyond planned BLA submission and launch preparation.

**【CMO Clinical Update】**
- AMT-130 Phase 1/2 trial:
  - Cohort 3 (n=12) showed AMT-130 generally safe/tolerable with immunosuppression
  - 3 immunosuppression-related SAEs resolved with standard care
  - Planning to present 3-year follow-up data in Q3 2025
- Other pipeline progress:
  - Fabry disease trial: 4 patients dosed, initial data expected H2 2025
  - SOD1-ALS trial: 2nd cohort enrollment complete
  - TLE trial: 1st patient dosed, interim data at epilepsy symposium May 29

**【Key Q&A Themes】**
- FDA interactions:
  - Productive meetings on BLA preparation and CMC validation
  - No impact expected from new CBER leadership
- Regulatory path:
  - BLA submission timing dependent on FDA meeting minutes
  - 3-year follow-up data will be primary analysis
- Commercial readiness:
  - >50 U.S. centers capable of administering AMT-130
  - Global partnerships under active consideration


Actual										-0.63	-0.96	-1.21	-0.01	-0.91	8.51	-0.79	0.23	-1	-0.84	-1.02	0.15	-1.63	-1.44	-1.88	-1.52	-1.36	-1.16	-0.91	-1.49	-0.82	-0.69	-1.38	-0.57
Forecast										-0.7213	-0.65	1.9853	-0.8525	-0.8935	2.9688	-1.049	-0.8215	-0.9319	-0.996	-1.1981	-0.8866	-0.9015	2.3635	-0.8545	-1.4551	-1.2792	-1.2532	-0.9927	-0.6529	-1.0013	-0.8948	-0.9028	-0.9167
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+12.66%	-47.69%	-160.95%	+98.83%	-1.85%	+186.65%	+24.69%	+128.00%	-7.31%	+15.66%	+14.87%	+116.92%	-80.81%	-160.93%	-120.01%	-4.46%	-6.32%	+7.44%	+8.33%	-128.21%	+18.11%	+22.89%	-52.86%	+37.82%

Actual	--	--	--	--	--	--	--	--	--	104.00K	1.53M	1.79M	34.19M	454.00K	463.87M	1.99M	57.69M	1.79M	497.00K	1.40M	102.70M	5.33M	2.42M	1.41M	6.68M	8.50M	11.13M	2.29M	5.22M	1.57M	5.26M	3.70M	5.57M
Forecast	--	--	--	--	--	--	--	--	--	1.34M	5.12M	133.27M	120.05M	2.27M	190.02M	2.52M	10.75M	17.66M	10.19M	3.48M	19.42M	30.30M	166.71M	29.49M	5.60M	6.29M	6.84M	6.86M	17.94M	6.36M	5.40M	5.79M	5.47M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-92.23%	-70.02%	-98.66%	-71.52%	-79.96%	+144.12%	-20.98%	+436.85%	-89.85%	-95.12%	-59.81%	+428.94%	-82.43%	-98.55%	-95.23%	+19.32%	+35.12%	+62.61%	-66.65%	-70.90%	-75.36%	-2.48%	-36.10%	+1.77%

QURE

QURE fundamentals

QURE Q4 2025 Earnings

Earnings Call

You can ask Aime

QURE

QURE fundamentals

QURE Q4 2025 Earnings

Earnings Call

QURE Earnings Call Summary for Q4/20258:00 AM on Mar 2, 2026

QURE Earnings Call Summary for Q3/20258:30 AM on Nov 10, 2025

QURE Earnings Call Summary for Q2/20258:30 AM on Jul 29, 2025

QURE Earnings Call Summary for Q1/20258:30 AM on May 9, 2025

QURE Earnings Call Summary for Q4/2024 Mar 28, 2026

You can ask Aime